The FDA will restart routine facility inspections after a few months of shelving.

(2020/07/14) A new generation of anti-flu drugs - Baloxavir marboxil; 2020 pharmaceutical industry pay rise announced; health care products market for the first time! TOP20 brand under 7.6 2 new listings; the third batch of national picks can not escape the fate of the fate of the price of "collecting drugs" where to go ..(Click on the title, get the original text) After a few months of shelving, the FDA will restart routine facilities inspections, FDA Director Stephen Hahn said in a statement on Friday (July 10) that the agency will prioritize the resumption of u.Sdomestic manufacturing inspections during the week of July 20as a safety measure for drug company employees, FDA investigators will announce their visit in advance, rather than conducting unplanned inspectionsheadlines: not a full recovery to the level of pre-epidemic restarts: A new generation of anti-flu drugs - Baloxavir marboxil 2018 first-in-class anti-flu drug Baloxavir marboxil is listed in multiple countries, according to the Evaluate Pharma database, Baloxavir marboxil worldwide sales reached $245 million in 2018compared to oseltamivir, Baloxavir marboxil has the advantage of no course of treatment (oseltamivir continuous treatment for 5 days), only one day administration, disease symptom relief time compared to oseltamivir, virus drops and safety than oseltamivir and other advantagesheadlines: Can a new generation of anti-flu drugs break through the domestic anti-flu market in Oseltami? "Cyber Blue" 2020 pharmaceutical industry pay increase sewage rate announced recently, the compensation analysis platform "salary intelligence" recently released the first half of 2020 market compensation white paperit is understood that in the first half of 2020, in the face of the sudden outbreak, some industries have been hit to varying degrees, and some industries in the outbreak of the trend of growthheadlines: There is still plenty of room for pay rise in the futurethe "Mininet" health care products market for the first time down! TOP20 brand under the 7.6 billion new list in 2019 the relevant departments of the state on the "health care" market rectification action, drug retail industry reform and norms, "e-commerce law" implementation and other factors superimposed, the industry suffered a full range of baptism, leading pharmaceutical company Thomson Bijian performance surprised the first loss, once caused industry shockheadlines: The health care market is under enormous pressure"Drug Intelligence Network" the third batch of national mining can not escape the fate of the price reduction of the "collection of medicine" where to go? Patent cliffs in the U.Spharmaceutical industry have helped reduce prices for generic drugs, and generics saved the U.Shealth care system $1.67 trillion between 2007 and 2016, according to IMS Health InstituteWhile generics have the same therapeutic effect as their branded drugs, the reduction in the cost of prior-period research means that they are often much less expensive to sellwhen multiple generic selling a single approved product, market competition usually results in prices about 85% lower than brandsheadlines: The original research drug is a long-overdue false proposition"E drug managers" high 2.2 billion to grab GSK, AZ 10 billion set to increase usher in a cooling blow? In the first half of the year, A-share biopharmaceutical non-public issuance of 5 months batch of 1, gaoyu capital fixed to increase KailaiYing blocked, and hand 2.2 billion fixed to increase health yuan, the cumulative "mind" spent more than 10 billion, but look at the rhythm of today, to really spend timeheadlines: The high-steaming shot looks like it's in the wind and fireThe Pharmaceutical Cube was approved as the biggest winner of the first half of 2020: Novartis approved 25 new drugs in the first half of 2020, a large increase from 14 in the same period in 2019;headlines: Novartis becomes the biggest winner.